Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,251 total articles

G-III Apparel Group Declares Quarterly Dividend

G-III Apparel Group Declares Quarterly Dividend

G-III Apparel Group, Ltd., a global fashion leader with a diverse brand portfolio, declared a quarterly cash dividend of $0.10 per share payable to shareholders on July 8, 2026. The announcement reflects the company's ongoing commitment to returning value to investors amid its extensive licensing and retail operations in the fashion sector.

Intchains Group to Present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on June 3-4

Intchains Group to Present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on June 3-4

Intchains Group Limited, a Nasdaq-listed company specializing in altcoin mining and staking, announced its participation in the Noble Capital Markets Emerging Growth Virtual Equity Conference scheduled for June 3-4, 2026. The company will present its business strategy and engage with investors through one-on-one meetings during the virtual event.

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology

Tonix Pharmaceuticals announced the publication of Phase 1 clinical data for TNX-1500, a novel Fc-modified anti-CD40L monoclonal antibody designed to prevent organ transplant rejection and treat autoimmune diseases. The study demonstrated favorable safety, tolerability, and pharmacodynamics in healthy adults, supporting the planned Phase 2 investig…

Lantronix Announces Preliminary Inclusion in Russell 3000® Index

Lantronix Announces Preliminary Inclusion in Russell 3000® Index

Lantronix Inc., a provider of Edge AI and Industrial IoT solutions, announced its preliminary addition to the Russell 3000 Index as part of the 2026 Russell indexes reconstitution. This inclusion is reflective of the company's strategic repositioning towards higher-growth and higher-value markets and is expected to enhance its visibility to institu…

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst Pharmaceuticals announces seven abstracts from its hereditary angioedema (HAE) portfolio to be presented at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting. The data focus on ORLADEYO (berotralstat), the first oral prophylactic therapy for HAE, and navenibart, an investigational monoclonal antibody for attack pr…

Korro to Present at the 2026 Jefferies Global Healthcare Conference

Korro to Present at the 2026 Jefferies Global Healthcare Conference

Korro Bio, a biopharmaceutical company specializing in RNA editing genetic medicines via its OPERA platform, announced CEO Ram Aiyar will present at the 2026 Jefferies Global Healthcare Conference. The presentation highlights Korro's innovative approach to developing treatments for rare and prevalent diseases by precisely editing RNA to enhance the…

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System

NRx Pharmaceuticals announced that its subsidiary, HOPE Therapeutics, has become the first commercial site to use Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its West Palm Beach clinic. The system integrates AI-powered, sub-millimetric image guidance to improve precision in Transcranial Magnetic Stimulation (TMS) treatment for major d…

Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol “SKYA”; Establishing Category-defining Agentic Finance Platform Serving Global South

Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol “SKYA”; Establishing Category-defining Agentic Finance Platform Serving Global South

Sharps Technology, Inc. has rebranded to SkyAI, Inc. and will trade on Nasdaq under the ticker 'SKYA'. The company is transitioning into building a category-defining agentic finance platform aimed at serving the Global South—emerging markets in Asia, Latin America, and Africa. SkyAI plans to leverage AI, stablecoins, and the Solana blockchain to pr…

Statement from the Supervisory Board of STMicroelectronics

Statement from the Supervisory Board of STMicroelectronics

Following the 2026 Annual General Meeting in Amsterdam, STMicroelectronics appointed Mr. Armando Varricchio as Chairman and Mr. Nicolas Dufourcq as Vice-Chairman of its Supervisory Board, with terms lasting until 2029. The company continues to emphasize its commitment to semiconductor innovation and sustainability goals, including carbon neutrality…

Bath & Body Works Reports First Quarter Results Exceeding Guidance and Progress Against the Consumer First Formula

Bath & Body Works Reports First Quarter Results Exceeding Guidance and Progress Against the Consumer First Formula

Bath & Body Works reported first quarter 2026 net sales of $1.4 billion, a 3% decline year-over-year, with adjusted earnings per share of $0.32 exceeding guidance. The company reaffirmed full-year 2026 guidance projecting net sales decline between 4.5% to 2.5% and adjusted EPS between $2.40 and $2.65. Leadership changes include CFO Eva Boratto step…

Scorpio Tankers Inc. Announces Agreements to Sell Four LR2 Product Tankers, a Letter of Intent to Purchase Two Newbuilding MRs and its Intention to Repay All Secured Debt Due 2028

Scorpio Tankers Inc. Announces Agreements to Sell Four LR2 Product Tankers, a Letter of Intent to Purchase Two Newbuilding MRs and its Intention to Repay All Secured Debt Due 2028

Scorpio Tankers Inc. has entered agreements to sell four LR2 product tankers for $285.8 million and signed a letter of intent to purchase two scrubber-fitted MR product tankers, expected for delivery in 2030. Additionally, the company plans to prepay approximately $367.8 million of secured debt due in 2028, leading to the termination of several cre…

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences, gaining up to $1.3 billion in flexible, non-dilutive capital to support the late-stage development and commercialization of its leading product candidate, Zumilokibart, targeting moderate-to-severe atopic dermatitis and other inflammatory and immunology…

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics announced highly positive 16-week results from Part B of its Phase 2 APEX clinical trial evaluating Zumilokibart, an anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis. The trial met all primary and secondary endpoints with strong statistical significance, demonstrating robust efficacy and a favorable saf…

PDD Holdings Announces First Quarter 2026 Unaudited Financial Results

PDD Holdings Announces First Quarter 2026 Unaudited Financial Results

PDD Holdings Inc. announced its unaudited financial results for Q1 2026, showing an 11% increase in total revenues to RMB106.2 billion (US$15.4 billion) and a 22% increase in operating profit to RMB19.6 billion (US$2.8 billion) compared to the same quarter in 2025. Despite these gains, net income attributable to ordinary shareholders declined by 15…

Nano Dimension Announces Sale of MarkForged, Inc. to Stratasys

Nano Dimension Announces Sale of MarkForged, Inc. to Stratasys

Nano Dimension has entered into a definitive agreement to sell its wholly owned subsidiary MarkForged, Inc. to Stratasys Ltd. in an all-cash transaction worth $42.5 million. This sale is a key part of Nano Dimension's three-phase strategic plan aimed at maximizing long-term shareholder value. The transaction is expected to reduce Nano Dimension's a…

Radware Reports Results of 2026 Annual General Meeting

Radware Reports Results of 2026 Annual General Meeting

Radware Ltd., a NASDAQ-listed leader in application security and delivery for multi-cloud environments, reported that all three proposals submitted at its 2026 Annual General Meeting were approved by shareholders. The company reaffirmed its leadership in AI-driven cybersecurity solutions and outlined the usual risks and forward-looking statements r…